Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

BACKGROUND: On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had unde...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Eggermont, A.M.M., Chiario-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J.D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P.A., Richards, J.M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J.S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J.C., Hodi, F.S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S., Testori, A.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5648545/
https://ncbi.nlm.nih.gov/pubmed/27717298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611299
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料